Erasca, Inc. (ERAS) vs Pfizer Inc. (PFE)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| ERAS | PFE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Drug Manufacturers - General |
| Size band | MID | LARGE |
| Listing | Nasdaq GS | NYSE |
| Country | United States | United States |
| Theme | oncology | pharmaceuticals-large-cap |
| Price and returns | ||
| Last close | $14.99 | $29.79 |
| Return · 1 week | +10.06% | +1.19% |
| Return · 1 month | +6.09% | +3.73% |
| Return · 3 months | −17.46% | +17.98% |
| Return · year to date | +317.55% | +22.28% |
| Return · 1 year | +527.20% | +26.49% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −38.26% | −2.14% |
| 52-week high | $24.28 | $30.44 |
| 52-week low | $2.11 | $23.62 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $5.24B | $169.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $62.01M | $929.52M |
| Employees | 103 | 75,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 39.00× |
| Price to earnings · forward | n/a (negative forward earnings) | 10.41× |
| Price to sales | — | 2.69× |
| Price to book | 11.56× | 2.01× |
| Enterprise value to EBITDA | n/a (negative value) | 8.80× |
| Enterprise value to revenue | — | 3.51× |
| PEG ratio | — | 13.76 |
| Earnings per share · trailing | -0.95 | 0.77 |
| Profitability | ||
| Gross margin | — | 73.18% |
| Operating margin | 0.00% | 27.88% |
| Profit margin | — | 6.81% |
| Return on equity | −78.25% | 5.01% |
| Return on assets | −21.39% | 5.78% |
| Growth | ||
| Revenue growth | — | +2.60% |
| Balance sheet and payout | ||
| Debt / equity (%) | 12.36 | 74.25 |
| Current ratio | 8.29 | 1.27 |
| Dividend yield | 0.00% | 5.73% |
| Payout ratio | — | 226.32% |
| Trend and volatility | ||
| RSI · 14 | 50.94 | 61.82 |
| ADX · 14 | 14.36 | 28.95 |
| 50-day average | $15.72 | $28.36 |
| 200-day average | $14.85 | $26.71 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 6.98% | 1.96% |
The full ERAS analysis
Everything this table leaves out for Erasca, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the ERAS argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full ERAS analysisThe full PFE analysis
Everything this table leaves out for Pfizer Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the PFE argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full PFE analysis